AbbVie Inc (ABBV)vsCelularity Inc (CELU)
ABBV
AbbVie Inc
$283.65
+3.32%
HEALTHCARE · Cap: $471.27B
CELU
Celularity Inc
$1.31
-7.75%
HEALTHCARE · Cap: $38.21M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 242408% more annual revenue ($64.39B vs $26.55M). ABBV leads profitability with a 9.8% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
CELU
Avoid18
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-84.3%
Fair Value
$152.52
Current Price
$283.65
$131.13 premium
Margin of Safety
+71.8%
Fair Value
$4.36
Current Price
$1.31
$3.05 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
ROE of -6367.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.54 suggests the stock is reasonably priced for its growth.
Bull Case : CELU
The strongest argument for CELU centers on Debt/Equity.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 75.1x leaves little room for execution misses.
Bear Case : CELU
The primary concerns for CELU are Market Cap, Profit Margin, Piotroski F-Score.
Key Dynamics to Monitor
CELU carries more volatility with a beta of 0.80 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.1B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (73/100 vs 18/100) and 10.2% revenue growth. CELU offers better value entry with a 71.8% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Celularity Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Celularity Inc. is a pioneering biotechnology company focused on regenerative medicine through its innovative cellular products derived from the placenta. The company is advancing a promising pipeline of allogeneic immunotherapies aimed at enhancing treatment outcomes for cancer patients and those with severe medical conditions, while reducing associated complications. With a strong leadership team and strategic partnerships, Celularity is positioned to become a significant force in the dynamic advanced therapeutics sector, addressing critical unmet medical needs and driving advancements in patient care.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?